TMCnet News
Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical TrialsCleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging on March 13, 2024. The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification. In two trials,1-2 the CREDENCE and PACIFIC-1 studies comprised a total of 513 patients who underwent coronary CT angiography, myocardial perfusion imaging with single photon emission CT (SPECT), and fractional flow reserve derived from CT (FFRCT). For patients with an abnormal Cleerly AI-QCT ISCHEMIA finding, a positive result was associated with an approximately 7-fold increase of adverse cardiovascular events during an 8-year follow-up. Collectively, this study shows that Cleerly AI-QCT ISCHEMIA, when used in conjunction with Cleerly LABS, can provide a 3-in-1 approach for the assessment of atherosclerosis, stenosis and ischemia. "This pivotal study was performed in two different international populations which shows that CCTA nalyzed with the Cleerly AI-QCT ISCHEMIA device provides an accurate assessment of coronary ischemia," said James P. Earls, MD, Chief Medical Officer of Cleerly. "These promising findings offer the possibility of a novel care paradigm for symptomatic coronary artery disease evaluation that performs comprehensive analysis of atherosclerosis, stenosis and ischemia from a single non-invasive CCTA test, which may offer the benefit of guiding clinical decision making for both coronary revascularization and medical therapy." These study results come after Cleerly announced that its Cleerly ISCHEMIA software device is billable using the new Category I CPT® code 75580. About Cleerly® Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Cleerly's approach is grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multi-center clinical trials. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: www.cleerlyhealth.com.
This study was sponsored by Cleerly, Inc. and journal article authors Hao Wang, MS; Chung Chan, PhD; Tami Crabtree, MS; Melissa Aquino, MS; James K. Min, MD; and James P. Earls, MD are employees of Cleerly, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326141869/en/ |
